305 related articles for article (PubMed ID: 23785428)
1. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.
Rosty C; Young JP; Walsh MD; Clendenning M; Sanderson K; Walters RJ; Parry S; Jenkins MA; Win AK; Southey MC; Hopper JL; Giles GG; Williamson EJ; English DR; Buchanan DD
PLoS One; 2013; 8(6):e65479. PubMed ID: 23785428
[TBL] [Abstract][Full Text] [Related]
2. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.
Rosty C; Young JP; Walsh MD; Clendenning M; Walters RJ; Pearson S; Pavluk E; Nagler B; Pakenas D; Jass JR; Jenkins MA; Win AK; Southey MC; Parry S; Hopper JL; Giles GG; Williamson E; English DR; Buchanan DD
Mod Pathol; 2013 Jun; 26(6):825-34. PubMed ID: 23348904
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Nosho K; Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Zepf D; Yan L; Longtine JA; Fuchs CS; Ogino S
Neoplasia; 2008 Jun; 10(6):534-41. PubMed ID: 18516290
[TBL] [Abstract][Full Text] [Related]
4. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.
Shima K; Morikawa T; Baba Y; Nosho K; Suzuki M; Yamauchi M; Hayashi M; Giovannucci E; Fuchs CS; Ogino S
Cancer Causes Control; 2011 Feb; 22(2):301-9. PubMed ID: 21140203
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
[TBL] [Abstract][Full Text] [Related]
8. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840
[TBL] [Abstract][Full Text] [Related]
10. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
11. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
12. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
[TBL] [Abstract][Full Text] [Related]
13. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
Imamura Y; Morikawa T; Liao X; Lochhead P; Kuchiba A; Yamauchi M; Qian ZR; Nishihara R; Meyerhardt JA; Haigis KM; Fuchs CS; Ogino S
Clin Cancer Res; 2012 Sep; 18(17):4753-63. PubMed ID: 22753589
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
15. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
[TBL] [Abstract][Full Text] [Related]
18. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
19. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.
Naito T; Nosho K; Ito M; Igarashi H; Mitsuhashi K; Yoshii S; Aoki H; Nomura M; Sukawa Y; Yamamoto E; Adachi Y; Takahashi H; Hosokawa M; Fujita M; Takenouchi T; Maruyama R; Suzuki H; Baba Y; Imai K; Yamamoto H; Ogino S; Shinomura Y
World J Gastroenterol; 2014 Aug; 20(29):10050-61. PubMed ID: 25110432
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
